⚕️ The information below is for educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Consult your healthcare provider before starting any medication or making changes to your treatment plan.
GLP-1 receptor agonists are among the most expensive medications in India's outpatient pharmaceutical market. A single pen of Ozempic (semaglutide 1 mg, 4 doses) costs Rs 8,000–10,000. Victoza (liraglutide) runs Rs 4,000–5,500 per pen. Mounjaro (tirzepatide), launched in India in 2024, costs Rs 12,000–18,000 per pen depending on dose. For patients requiring these medications long-term, the annual cost can exceed Rs 1–2 lakh — a substantial burden even for middle-class households.
Health insurance coverage of GLP-1 medications in India is inconsistent, often poorly understood, and varies dramatically between policies, insurers, and whether the indication is diabetes or obesity. This guide cuts through the confusion.
Question 1: Is your hospitalisation covered? If you are admitted to hospital for a complication related to diabetes or obesity (diabetic ketoacidosis, cardiac event, severe hypoglycaemia), your hospitalisation costs will generally be covered under standard health insurance. This is not specific to GLP-1 medications.
Question 2: Are your outpatient GLP-1 medication costs covered? This is where the real challenge lies — and it is the question most patients care about. The answer is complicated.
Standard health insurance in India is designed primarily for inpatient hospitalisation. Outpatient drug costs — including ongoing medications for chronic conditions — are generally not covered under traditional indemnity health insurance policies.
This means that for most Indian policyholders with standard Mediclaim or family floater plans, GLP-1 medication costs are entirely out-of-pocket, regardless of whether the indication is diabetes or obesity.
However, several exceptions and workarounds exist:
Many major insurers now offer OPD riders or add-on covers that reimburse outpatient expenses including doctor consultations and prescribed medications. Key details:
For patients spending Rs 8,000–10,000 monthly on semaglutide, an OPD rider of Rs 10,000/year provides minimal offset. However, every rupee of reimbursement helps, and patients should utilise OPD benefits for consultations (diabetologist, dietitian) and lower-cost medications that free up budget for GLP-1 costs.
CGHS (Central Government Health Scheme): Government employees covered under CGHS can get GLP-1 medications reimbursed if the indication is type 2 diabetes and the medication is on the CGHS formulary. As of 2025:
CGHS beneficiaries should check the latest formulary with their nearest CGHS Wellness Centre and ask their diabetologist for a prescription with the ICD-10 code for type 2 diabetes (E11).
ECHS (Ex-Servicemen Contributory Health Scheme): Similar formulary to CGHS; liraglutide-based agents are generally available. Check with your ECHS Polyclinic.
PSU and state government employees: Reimbursement policies vary by organisation. Employees of large PSUs (ONGC, NTPC, Indian Railways) typically have medical reimbursement schemes that cover prescribed medications for chronic disease. Submit claims with original prescription, bills, and medical records showing diabetes diagnosis.
Large corporates increasingly include chronic disease management benefits in their group health policies. Key developments:
If you are employed at a large organisation, speak to your HR or benefits team and ask specifically:
Diabetes-specific insurance products (offered by Star Health, Niva Bupa, and others) are designed for people with pre-existing diabetes. These policies sometimes include medication coverage as part of disease management programmes. Examples:
These policies are worth considering for newly diagnosed type 2 diabetes patients — though pre-existing condition waiting periods (typically 2–4 years) may apply.
While not insurance coverage per se, Section 80D of the Income Tax Act allows you to claim a deduction for medical expenses if you do not have health insurance — including for chronic conditions like diabetes. The maximum deduction is Rs 50,000 for senior citizens.
More relevant: Section 80D also covers health insurance premiums up to Rs 25,000/year (Rs 50,000 for senior citizens). Paying for a policy with OPD add-on cover and claiming the premium under 80D partially offsets the cost.
Additionally, prescribed medications for chronic disease (including GLP-1 agents for diabetes) may qualify for HRA exemption calculation in some employer reimbursement schemes. Consult a chartered accountant.
Pull out your current health insurance policy document and look for:
If you cannot find this, call your insurer's helpline and ask explicitly: "Does my policy cover outpatient prescription medications for type 2 diabetes?"
If you have type 2 diabetes and your doctor has prescribed a GLP-1 agent for diabetes management, the prescription should clearly state:
Prescriptions written primarily for weight loss (even in diabetics) may be rejected by insurers. Your diabetologist can advise on correct prescription language.
For any reimbursement claim, maintain:
Novo Nordisk India (maker of Ozempic and Victoza) operates a patient support programme. Ask your doctor or contact Novo Nordisk India directly about any ongoing assistance programmes that may reduce medication costs.
Semaglutide injections from Indian manufacturers are expected to enter the market. Some liraglutide biosimilar products are already available at lower prices. Ask your doctor whether a biosimilar or equivalent product is clinically appropriate for you.
There are positive signals. IRDAI (Insurance Regulatory and Development Authority of India) has been pushing insurers to expand OPD and chronic disease management coverage. Several major insurers launched enhanced plans with meaningful OPD benefits in 2023–2025. As the prevalence of type 2 diabetes and obesity continues to rise in India — and as GLP-1 medications gain greater clinical recognition — pressure on insurers to include these drugs in formularies will grow.
For now, the reality is that most Indian patients pay for GLP-1 medications out-of-pocket. Knowing your rights, your policy's terms, and the available assistance options can meaningfully reduce that burden.
